Hematology Oncology of Indiana, a Division of American Oncology Network

• Partner

Indy Hematology Education Inc.

• President and CEO

Marian University: Wood College of Osteopathic Medicine

• Clinical Professor

Ruemu E. Birhiray, MD is an attending physician in medical oncology, hematology, and hematopoietic stem cell transplantation at Hematology-Oncology of Indiana, and at St. Vincent Hospital in Indianapolis, Indiana. After completing his internal medicine residency at Columbus Hospital in Chicago where he also served as Chief Medical Resident in 1994, he was a postgraduate fellow in bone marrow transplant at Johns Hopkins University in Baltimore and in medical oncology at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland where his research included gene therapy and adoptive cellular immunotherapy strategies in bone marrow transplantation. Dr. Birhiray’s professional experience has also included serving as an attending physician, and Director of bone marrow transplantation and a member of Marshfield Clinic, Wisconsin and a Clinical Assistant Professor at the University of Wisconsin from 1998 to 2001. Additionally Dr. Birhiray was appointed an Associate Professor of bone marrow transplantation at Rush University, Chicago, Illinois in 2001, prior to joining Hematology Oncology of Indiana. Subsequently, Dr. Birhiray, served as and director of Bone Marrow Transplantation and Institutional Principal Investigator for the National Surgical Adjuvant Breast and Bowel Project of the National Cancer Institute at St. Vincent’s Hospital, Indianapolis. Currently, he is also, Clinical Professor, Marian University School of Osteopathic Medicine, Indianapolis, Indiana, and an Editorial Board Member of The Journal of Blood Transfusion and Hematopathology. Projects for which Dr. Birhiray is principal investigator include reduced intensity allogeneic transplantation in hematologic malignancies, and a trial of Interferon A, CHOP, and rituximab therapy in advanced-stage follicular lymphoma, and neoadjuvant chemotherapy for breast cancer. Additional collaborations have included major phase III clinical trials. Additionally Dr. Birhiray founded the Clinical research program at Hematology Oncology of Indiana. His awards include, “Intern of the year” from Columbus Hospital, Hope award from the Indiana Wellness community and named “best physician” by the Indianapolis monthly magazine and “top doctor” by Castle Connelly. In 2002, Dr. Birhiray founded and has served as Chair of the annual “Indy Hematology Review”, a nationally respected program providing education for hematologists and oncologists nationally and regionally, and he is also President and CEO of Indy Hematology Education, Inc. A member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Medical Association, Dr Birhiray has published in the Journal of Clinical Oncology, Leukemia, Gene Therapy and Therapeutic Apheresis, Journal of Blood Transfusion and Hematopathology, Human Immunology, Familial Cancer, Annals of Pharmacotherapy, American Journal of Health System Pharmacists, Pharmacotherapy, in addition to multiple abstracts. Dr. Birhiray is married to Donna Marie (nee Baynard) since 1995, and they are blessed with 3 children, a daughter, Maya, born in 1999, and a son, Dirin, born in 2003, and an older daughter Meaghan who was born in 1990.

Moffitt Cancer Center

• Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy

• Program Lead, Blood and Marrow Transplant and Cellular Immunotherapy

• Program Co-Leader, Immuno-Oncology; Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy.

Dr. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr. Locke graduated with a B.S. in Physiology from Michigan State University, and with an M.D. from Wayne State University. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. Dr. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago. Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.

Dana-Farber Cancer Institute

• Chief of Staff

• Director of Translational Research, Adult Leukemia Program

• Institute Physician

Harvard Medical School

• Professor of Medicine

Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

Dana-Farber Cancer Institute

• Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center

• Kraft Family Chair

• Director, Multiple Myeloma Immune Effector Cell Therapy

• Senior Physician

Harvard Medical School

• Professor of Medicine

Dr. Munshi received his MD from Maharaja Sayjirao University, India, in 1984. He completed his postgraduate training in Internal Medicine at SSG Hospital and Maharaja Sayjirao University, followed by fellowships at Johns Hopkins Oncology Center and Indiana University Medical Center. In 2001, he joined Dana-Farber Cancer Institute and is currently the Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center.

Mission Cancer + Blood

• Medical Oncologist

Dr. Mustafa Khasraw, MD, FRACP, MRCP is a physician-scientist with a background in medical oncology and neuro-oncology, with affiliations to multiple departments, research, and training programs at Duke. Dr. Khasraw leads a Tumor Immunobiology Laboratory using various wet and dry lab techniques to understand the interactions between tumors and the immune system. The goal of his lab is to identify vulnerabilities that can be targeted for novel therapies.

Dr. Graff obtained her master’s degree in Immunology from Loyola University in Chicago and earned her Doctor of Osteopathic Medicine credentials from Lake Erie College of Osteopathic Medicine in Bradenton, Florida in 2009.

She completed her residency training in Internal Medicine and a fellowship in Hematology and Oncology at the Medical College of Wisconsin at Froedtert Memorial Lutheran Hospital. She has led several clinical research projects and has published many original oncology and hematology articles. Dr. Graff is board certified in both Internal Medicine and Medical Oncology.

Dr. Graff has worked at Mission Cancer and Blood in Des Moines IA for the over 9 years specializing in CLL and NHL.

Dr. Graff serves on the BMS National CAR-T Cell Advisory Board for Lymphoma as well as sitting on multiple National Lymphoma Advisory Boards, NHL Advisory Council and LBCL Steering Committee. She is a member of ECOG Clinical Trial Organization, Lymphoma Working Committee for the CIBMTR and sits on the Lymphoma Research Foundation (LRF). She has paired with LLS doing patient education for rural cancer patients as well as CAR-T and bispecific education for community oncologists. Dr. Graff is the cellular therapy lead for Exigent Research as well as co-chair for the malignant hematology council for Exigent Research. She is an educational speaker for many companies and is trained in MRD interpretation through Adaptive Biotech.

Dr. Graff serves as the Primary Investigator for multiple clinical trials both past and present and is Physician Champion and Lead for Mission Cancer and Blood Clinical Trials Program.

She is the recipient of the 2023 Q2 Targeted Oncology ICONS Award and has been Nominated for Visionary of the Year by the leukemia and lymphoma society for 2024.

The Center for Cancer and Blood Disorders

• Medical Director

• Founder

American Oncology Network

• Chief Medical Officer

Georgetown University

• Clinical Associate Professor of Medicine

Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland.

Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health.

Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation.

Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly.

Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet.